Chromosomal aberrations associated with invasion in papillary superficial bladder cancer

Non‐invasive and invasive papillary transitional cell carcinomas of stages pTa and pT1 represent the first steps of tumour progression in bladder cancer. In order to analyse different chromosomal alterations of pTa and pT1 superficial bladder cancer, 46 tumour specimens were examined by comparative genomic hybridization (CGH). Losses of chromosome 9 material (11/20) and gains of chromosome 17 material (6/20) were frequently found in pTa tumours. Stage pT1 tumours were characterized by gains of chromosome 1q (14/26; including amplification at 1q21–q24 in three cases) and chromosome 17 material (15/26), as well as by losses of 11p (15/26) and 11q (13/26). Other loci frequently showing losses in pT1 tumours were 2q (9/26), 4q (10/26), 5q (9/26), 8p (10/26), 9p (9/26), 9q (12/26), 10q (8/26), 17p (7/26), and 18q (8/26). Amplifications were detected at 8q21/22, 5q21, 7q36, 10p14, 10p12, 10q25, 12q12, and 12q14. The most striking differences between grade 2 pTa and pT1 tumours were gains of 1q (P<0·01) and losses at 2q (P<0·025), 10q (P<0·05), 11p (P<0·01), 11q (P<0·01), and 17p (P<0·05), as well as the total number of aberrations (pTa grade 2: 4·1; pT1 grade 2: 8·6 aberrations per tumour). These data show characteristic chromosomal aberrations associated with invasion in superficial bladder cancer. © 1998 John Wiley & Sons, Ltd.

[1]  L. Sobin,et al.  Histological Typing of Urinary Bladder Tumours , 1999, International Histological Classification of Tumours.

[2]  H. Moch,et al.  Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. , 1997, Cancer research.

[3]  W. Fair,et al.  The treated natural history of high risk superficial bladder cancer: 15-year outcome. , 1997, The Journal of urology.

[4]  C. Cordon-Cardo,et al.  Alterations of tumor suppressor genes in bladder cancer. , 1997, Seminars in diagnostic pathology.

[5]  F. Lampert,et al.  COMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMAS—AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGY , 1997, The Journal of pathology.

[6]  E. Holmberg,et al.  The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. , 1997, The Journal of urology.

[7]  M. Pierotti,et al.  Genomic organization of the human NTRK1 gene. , 1996, Oncogene.

[8]  R. Blelloch,et al.  A molecular genetic model of human bladder cancer pathogenesis. , 1996, Seminars in oncology.

[9]  F. Waldman,et al.  Renal cell carcinoma genetic analysis by comparative genomic hybridization and restriction fragment length polymorphism analysis. , 1996, The Journal of urology.

[10]  E. Okajima,et al.  Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. , 1996, Cancer letters.

[11]  E. Schuuring,et al.  Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. , 1996, Oncogene.

[12]  J. Wesseling,et al.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.

[13]  T. Shuin,et al.  Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer. , 1996, The Journal of urology.

[14]  C. Voorter,et al.  Loss of chromosome 11 and 11 P/Q imbalances in bladder cancer detected by fluorescence in situ hybridization , 1996, International journal of cancer.

[15]  Patricia A. Elder,et al.  Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. , 1995, Oncogene.

[16]  M. Williamson,et al.  p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. , 1995, Human molecular genetics.

[17]  T C Gasser,et al.  Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. , 1995, Cytometry.

[18]  M. Knowles,et al.  Deletion mapping of chromosome II in carcinoma of the bladder , 1995 .

[19]  P. Carroll,et al.  c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. , 1995, The American journal of pathology.

[20]  P. Carroll,et al.  Chromosome‐9 loss detected by fluorescence in situ hybridization in bladder cancer , 1995, International journal of cancer.

[21]  S. Devries,et al.  Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization , 1995, Genes, chromosomes & cancer.

[22]  E. Mallon,et al.  Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ , 1995, International journal of cancer.

[23]  T. Visakorpi,et al.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.

[24]  P. Carroll,et al.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. , 1994, The American journal of pathology.

[25]  R. Gardiner,et al.  Mucin expression by transitional cell carcinomas of the bladder. , 1994, British journal of urology.

[26]  A. Sandberg,et al.  Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. , 1994, The Journal of urology.

[27]  J. Cairns,et al.  Allelotype of human bladder cancer. , 1994, Cancer research.

[28]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[29]  R. Brent,et al.  Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites , 1993, Cell.

[30]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[31]  S. Hughes,et al.  The ski oncogene. , 1991, Oncogene.

[32]  Y. Nakamura,et al.  Twenty-eight loci form a continuous linkage map of markers for human chromosome 1. , 1989, Genomics.

[33]  W. Murphy,et al.  Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? , 1987, Cancer.

[34]  A. Sandberg,et al.  Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. , 1984, Cancer research.

[35]  D. Carr.  The manual for the staging of cancer. , 1977, Annals of internal medicine.

[36]  T. Visakorpi,et al.  Genetic basis and clonal evolution of human prostate cancer. , 1996, Advances in cancer research.

[37]  P. Lichter,et al.  Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. , 1995, The American journal of pathology.

[38]  C. Cordon-Cardo,et al.  Genetic alterations associated with bladder cancer. , 1994, Important advances in oncology.

[39]  G. Kovacs,et al.  Molecular cytogenetics of renal cell tumors. , 1993, Advances in cancer research.

[40]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.